Lupin launches generic Glumetza HCI ER Tablets in US

02 Feb 2016 Evaluate

Lupin’s US subsidiary, Lupin Pharmaceuticals Inc. has launched its Metformin HCI ER Tablets, 500 mg and 1000 mg to market a generic equivalent of Santarus Inc.’s Glumetza HCI ER Tablets, 500 mg and 1000 mg.

Lupin’s Metformin HCI ER Tablets, 500 mg and 1000 mg are the AB-rated generic equivalent of Santarus Inc.’s Glumetza HCI ER Tablets, 500 mg and 1000 mg strengths. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes mellitus.

Lupin is eligible for 180 days of generic drug exclusivity for its Metformin HCI ER Tablets, 500 mg and 1000 mg. Glumetza HCI ER Tablets had US sales of $450.4 million, as per IMS MAT September 2015.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.


Lupin Share Price

2055.05 3.00 (0.15%)
10-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.25
Dr. Reddys Lab 1251.10
Cipla 1489.15
Zydus Lifesciences 923.70
Lupin 2055.05
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×